Orticumab (MLDL1278A) is a recombinant human monoclonal antibody engineered to specifically bind to epitopes on oxidized low-density lipoprotein (oxLDL). it demonstrates therapeutic potential by modulating autoimmune responses against oxLDL, thereby improving atherosclerotic plaque pathology, and also shows significant promise for the treatment of autoimmune inflammatory conditions such as psoriasis.
Purity:
95%
CAS Number:
[1314241-10-5]
Target:
LDLR|||LDL
* VAT and and shipping costs not included. Errors and price changes excepted
